Zacks Research Estimates Haemonetics’ Q4 Earnings (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research lifted their Q4 2026 earnings per share estimates for shares of Haemonetics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $1.40 per share for the quarter, up from their prior estimate of $1.39. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics’ FY2027 earnings at $5.92 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The firm had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. During the same period in the prior year, the firm posted $0.99 EPS. The company’s revenue for the quarter was up 8.6% on a year-over-year basis.

Several other equities analysts have also recently commented on the stock. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a research report on Friday, November 8th. BTIG Research started coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $112.00 price target on shares of Haemonetics in a research note on Tuesday, December 3rd. Barrington Research reiterated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a report on Wednesday, December 4th. Finally, Bank of America initiated coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price on the stock. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Trading Down 1.2 %

Shares of HAE stock opened at $82.30 on Thursday. The stock has a market cap of $4.13 billion, a P/E ratio of 34.17, a price-to-earnings-growth ratio of 1.26 and a beta of 0.38. Haemonetics has a 1 year low of $70.25 and a 1 year high of $97.97. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The stock has a 50 day simple moving average of $80.91 and a 200 day simple moving average of $81.63.

Institutional Investors Weigh In On Haemonetics

Several institutional investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC raised its holdings in Haemonetics by 3.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock valued at $304,000 after acquiring an additional 117 shares during the period. Vontobel Holding Ltd. increased its holdings in shares of Haemonetics by 3.8% in the third quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock worth $392,000 after purchasing an additional 180 shares during the period. QRG Capital Management Inc. raised its position in Haemonetics by 6.9% during the second quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier’s stock valued at $333,000 after purchasing an additional 260 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Haemonetics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock valued at $1,176,000 after buying an additional 272 shares in the last quarter. Finally, Keene & Associates Inc. lifted its position in Haemonetics by 3.0% in the 3rd quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock worth $818,000 after buying an additional 298 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.